Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Shots:

  • The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio
  • Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, medical affairs, manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months
  • Imetelstat is currently evaluated in IMbark P-II & IMerge P-II for r/r Myelofibrosis and Myelodysplastic syndromes respectively. Geron further plans to initiate IMerge P-III for Imetelstat for Myelodysplastic syndromes

Click here to read full press release/ article | Ref: Geron | Image: Google Plus